Compare AbCellera Biologics Inc (ABCL) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Star Bulk Carriers Corp — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Star Bulk Carriers Corp trades at $26.44 (market cap $2.92B). The key difference: Star Bulk Carriers Corp is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 3.93% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SBLK | |
|---|---|---|
Market Cap | $2.35B | $2.92B |
Sector | Health | Industrials |
52-Week High | $8.12 | $28.21 |
52-Week Low | $2.78 | $16.79 |
Enterprise Value | $1.99B | $3.62B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Star Bulk Carriers (SBLK) trades at $26.12, up 3.86% with bullish technical signals and strong earnings momentum after beating Q1 2026 estimates. The company shows solid fundamentals with 13.01% net income margin and positive cash flow, supported by a new dividend policy returning 100% of free cash flow. Analyst consensus is strongly bullish with 14 buy ratings.
SBLK presents a compelling investment case with earnings growth acceleration and shareholder-friendly capital allocation. Key risks include dry bulk market volatility and oil price sensitivity, but strong institutional support and technical momentum suggest continued upside potential for disciplined investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
